"Clinical Research Centre conducting clinical trials across a range of different therapeutic areas."

During the past decade, Emeritus Research conducted 65 clinical trials. In the 10-year time frame, 65 clinical trials started and 38 clinical trials were completed, i.e. on average, 58.5% percent of trials that started reached the finish line to date. In the past 5 years, 46 clinical trials started and 22 clinical trials were completed. i.e. 47.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Emeritus Research" #1 sponsor was "Pfizer" with 26 trials, followed by "Eli Lilly and Company" with 11 trials sponsored, "Novavax" with 5 trials sponsored, "Endo Pharmaceuticals" with 4 trials sponsored and "Gilead Sciences" with 4 trials sponsored. Other sponsors include 37 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Emeritus Research" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "PPD" with 3 trials as a collaborator, "Dermira, Inc." with 2 trials as a collaborator, "Galapagos NV" with 2 trials as a collaborator and "Gilead Sciences" with 2 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Emeritus Research" are "Psoriatic Arthritis" (9 trials), "Osteoarthritis, Knee" (6 trials), "Arthritis, Rheumatoid" (5 trials), "Atopic Dermatitis" (5 trials) and "Influenza" (5 trials). Many other conditions were trialed in "Emeritus Research" in a lesser frequency.

Most popular intervention types in "Emeritus Research" are "Drug" (65 trials), "Biological" (26 trials), "Other" (9 trials), "Combination Product" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (38 trials), "CP-690,550" (5 trials), "Baricitinib" (4 trials), "Filgotinib" (4 trials) and "Adalimumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Emeritus Research" are 89 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are 25 active trials in "Emeritus Research". 1 are not yet recruiting, 11 are recruiting, 11 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 55 completed trials in Emeritus Research, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Emeritus Research, 8 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 45 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 12 trials, and there were also 1 trials that are defined as “Not Applicable".